Deutsche Bank AG Invests $2.37 Million in Immunome, Inc. $IMNM

Key Points

• Deutsche Bank acquired 111,593 Immunome shares worth approximately $2.37 million during the second quarter, giving it about a 0.10% stake. Institutional investors collectively own 44.58% of the company.
• Immunome shares opened at $28.87, near their 52-week high of $30.06, despite the company reporting a quarterly loss of $0.65 per share—worse than the $0.51 consensus estimate.
• Analyst sentiment remains broadly positive, with 12 Buy ratings and one Sell rating, a “Moderate Buy” consensus, and an average price target of $34.64. However, insiders have sold 682,310 shares worth about $15.7 million over the past 90 days.

Deutsche Bank AG bought a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 111,593 shares of the company's stock, valued at approximately $2,365,000. Deutsche Bank AG owned approximately 0.10% of Immunome at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock valued at $60,000 after buying an additional 2,909 shares in the last quarter. KBC Group NV purchased a new stake in shares of Immunome during the 1st quarter worth approximately $60,000. Strs Ohio purchased a new stake in shares of Immunome during the 4th quarter worth approximately $64,000. Tower Research Capital LLC TRC boosted its position in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock valued at $65,000 after acquiring an additional 3,802 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new position in shares of Immunome during the 3rd quarter valued at approximately $76,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Insider Activity

In related news, Director Isaac Barchas sold 101,050 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00. Following the sale, the director directly owned 308,504 shares of the company's stock, valued at $6,515,604.48. This represents a 24.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the firm's stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $19.85, for a total transaction of $1,091,750.00. Following the completion of the sale, the insider directly owned 15,805 shares of the company's stock, valued at approximately $313,729.25. The trade was a 77.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 682,310 shares of company stock valued at $15,675,566. 7.21% of the stock is currently owned by company insiders.

Immunome Stock Up 0.4%

NASDAQ IMNM opened at $28.87 on Friday. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $30.06. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of -11.41 and a beta of 2.08. The company has a fifty day moving average of $24.02 and a two-hundred day moving average of $22.41.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Equities research analysts anticipate that Immunome, Inc. will post -2.38 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Immunome from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a research report on Friday, July 17th. Barclays began coverage on shares of Immunome in a research note on Thursday, May 28th. They issued an "overweight" rating and a $36.00 price objective for the company. Truist Financial boosted their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Finally, Wedbush upped their target price on shares of Immunome from $31.00 to $35.00 and gave the company an "outperform" rating in a research report on Wednesday, August 12th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immunome currently has a consensus rating of "Moderate Buy" and an average price target of $34.64.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source